Literature DB >> 28699235

Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.

Ayaka Katayama1, Tadashi Handa1, Kei Komatsu1, Maria Togo1, Jun Horiguchi2, Masahiko Nishiyama3, Tetsunari Oyama1.   

Abstract

Claudins (CLDNs) are key cell adhesion molecules, which compose tight junctions (TJs), and the disruption of TJs is associated with cancer development. Here we immunohistochemically studied expression patterns of CLDNs in 222 primary invasive breast cancers including 68 triple-negative breast cancers (TNBCs), and examined their correlation with epithelial-to-mesenchymal transition (EMT)-related markers, breast cancer stem cell (BCSC) markers, and clinicopathological features including patients' clinical outcome. Tumor margins were classified as three infiltrating growth patterns (expanding, intermediate and infiltrating). For CLDN1, 3, 4, and 7, their expression rates were more frequent in TNBCs than in other subtypes (11.8% vs 0.7%, 26.5% vs 2.0%, 48.5% vs 11.1%, and 32.4% vs 8.7%, respectively; P ≤ 0.001). In 68 TNBCs, we identified high Ki67 labeling index (LI) and the combination of CLDN4 high/CLDN7 low expression as independent predictors of axillary nodal metastasis (P = 0.019; OR, 4.36; 95%CI, 1.28-14.90 and P = 0.007; OR, 5.33; 95%CI, 1.58-17.90). Moreover, the combination of CLDN1 low/CLDN7 low/E-cadherin negative as well as tumor infiltrating patterns were predictors for worse recurrence-free survival by univariate analyses in TNBCs (P = 0.005 and P = 0.011). Our analyses provide further evidence that CLDNs would be valuable prognostic markers in TNBCs.
© 2017 Japanese Society of Pathology and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  E-cadherin; claudin-low; epithelial-to-mesenchymal transition; triple-negative breast cancer

Mesh:

Substances:

Year:  2017        PMID: 28699235     DOI: 10.1111/pin.12560

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  13 in total

Review 1.  Racial disparity in breast cancer: can it be mattered for prognosis and therapy.

Authors:  Vijayalaxmi Gupta; Inamul Haque; Jinia Chakraborty; Stephanie Graff; Snigdha Banerjee; Sushanta K Banerjee
Journal:  J Cell Commun Signal       Date:  2017-11-29       Impact factor: 5.782

2.  ΔNp63α exerts antitumor functions in cervical squamous cell carcinoma.

Authors:  Ying Zhou; Hanyuan Liu; Juan Wang; Xiaolin Wang; Lili Qian; Fei Xu; Weiguo Song; Dabao Wu; Zhen Shen; Dingqing Feng; Bin Ling; Weihua Xiao; Ge Shan; Liang Chen
Journal:  Oncogene       Date:  2019-10-01       Impact factor: 9.867

Review 3.  Claudins as biomarkers of differential diagnosis and prognosis of tumors.

Authors:  Olga P Popova; Alla V Kuznetsova; Svetlana Yu Bogomazova; Alexey A Ivanov
Journal:  J Cancer Res Clin Oncol       Date:  2021-07-09       Impact factor: 4.553

4.  High expression of forkhead box protein C2 is associated with aggressive phenotypes and poor prognosis in clinical hepatocellular carcinoma.

Authors:  Yuki Shimoda; Yasunari Ubukata; Tadashi Handa; Takehiko Yokobori; Takayoshi Watanabe; Dolgormaa Gantumur; Kei Hagiwara; Takahiro Yamanaka; Mariko Tsukagoshi; Takamichi Igarashi; Akira Watanabe; Norio Kubo; Kenichiro Araki; Norifumi Harimoto; Ayaka Katayama; Toshiaki Hikino; Takaaki Sano; Kyoichi Ogata; Hiroyuki Kuwano; Ken Shirabe; Tetsunari Oyama
Journal:  BMC Cancer       Date:  2018-05-25       Impact factor: 4.430

5.  Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray.

Authors:  Angela Flávia Logullo; Fatima Solange Pasini; Suely Nonogaki; Rafael Malagoli Rocha; Fernando Augusto Soares; Maria Mitzi Brentani
Journal:  Mol Clin Oncol       Date:  2018-07-27

6.  Hypomethylation at non-CpG/CpG sites in the promoter of HIF-1α gene combined with enhanced H3K9Ac modification contribute to maintain higher HIF-1α expression in breast cancer.

Authors:  Chun Li; Wei Xiong; Xiong Liu; Wenjun Xiao; Yuxian Guo; Junyu Tan; Yaochen Li
Journal:  Oncogenesis       Date:  2019-04-02       Impact factor: 7.485

7.  Polymorphisms in CLDN1 are associated with age and differentiation of triple-negative breast cancer patients.

Authors:  Aimin Hu; Junyu Li; Shufang Ruan; Ying Fan; Yuqian Liao
Journal:  Biosci Rep       Date:  2019-04-23       Impact factor: 3.840

8.  DDX5 Silencing Suppresses the Migration of Basal cell Carcinoma Cells by Downregulating JAK2/STAT3 Pathway.

Authors:  Zhe Quan; Bei-Bei Zhang; Fang Yin; Jiru Du; Yuan-Ting Zhi; Jin Xu; Ningjing Song
Journal:  Technol Cancer Res Treat       Date:  2019 Jan-Dec

9.  The Cytoplasmic Expression Of CLDN12 Predicts An Unfavorable Prognosis And Promotes Proliferation And Migration Of Osteosarcoma.

Authors:  Xiaoqing Tian; YinFeng He; Zhe Han; HongMin Su; Chao Chu
Journal:  Cancer Manag Res       Date:  2019-11-01       Impact factor: 3.989

10.  Targeting claudin-4 enhances chemosensitivity in breast cancer.

Authors:  Yi Luo; Shingo Kishi; Takamitsu Sasaki; Hitoshi Ohmori; Rina Fujiwara-Tani; Shiori Mori; Kei Goto; Yukiko Nishiguchi; Takuya Mori; Isao Kawahara; Masuo Kondoh; Hiroki Kuniyasu
Journal:  Cancer Sci       Date:  2020-03-18       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.